ANZCTR search results

Clinical safety study to assess the safety, feasibility and acceptability of a long-term, continuous monitoring, wearable electroencephalography (EEG) device in ischemic stroke patients. The device will be worn for 9 hours by 20 patients with acute ischemic stroke. Eligible participants will have already received treatment and will be in the stroke ward being monitored for at least 9 hours. Participants will be asked to complete a questionnaire at 1, 3, 6 and 9 hours to assess device comfort, acceptability and user experience. Safety will be assessed by the number of adverse events. Feasibility will be assessed as the number of hours of viable data as a percentage of the total recording time. The device will not interfere with standard care.

This study will be conducted as an online trial. All treatment packages will be shipped to the participant's postage address. Recruitment, and treatment application will be conducted in the participant's residence. This trial will evaluate the effectiveness and safety of new gel (Soodox Active) to reduce pain in hand osteoarthritis. It will be compared to another gel (Voltaren) that is widely used in current practice for a range of pain types and is considered the gold-standard commercial product. The effects on pain will then be measured in both using a 0-100mm Visual Analogue Scale, 100 being the worst pain and 0 being no pain. The participant's quality of life and hand function will also be measured using standardised questionnaires.

The aim of this study is to determine whether treatment with prescribed medicinal cannabis (containing delta 9-THC) for long-term symptom control impacts driving and cognitive/psychomotor performance. This will be assessed after 4, 8 and 12 weeks of treatment and examined relative to pre-treatment performance in a group of chronic non-cancer pain patients.

This is a single-arm, open-label study to evaluate the feasibility and effectiveness of long acting antiretroviral therapy in a "real world" setting, with inclusion of patients with complex social and medical needs and who have been under-represented in randomised clinical trials. Standard assessments of virological suppression and tolerability will be carried out however the study will primarily assess adherence to injections, qualitative aspects of the patient experience and satisfaction with injections as long-term therapy by both patients and providers, compared with patients' previously prescribed oral regimens. The study will also aim to describe the operational changes in clinical service required to deliver LA therapy and the patient and health-service characteristics associated with best outcomes.

The aim of this study is to use focus groups to evaluate the acceptability of blood tests and other tests to monitor the treatment of oesophageal, stomach and bowel cancers. Who: You are eligible to join this study if you are aged over 18 years old and have either (1) had treatment for oesophageal, stomach or bowel cancer, (2) provided a support role for someone who has had one of these cancers, or (3) are a clinician who provides clinical care and treatment for these cancers. Study details: All consented participants will take part in a phone interview to collect background details, followed by a 45 minute focus group at the Flinders Centre for Innovation in Cancer, Bedford Park, South Australia. Focus groups will include discussions on the knowledge, trust and experience with tests for monitoring of treatment for oesophageal, stomach and bowel cancers, in particular, blood tests. This research will help to determine the acceptability of different test methods for clinical care, by patients, carers and clinicians. This will help to improve clinical care strategies for cancer.

This study aims to Assess if implementation of an electronic exercise prescription software in the form of a smart phone app improves patient adherence, outcomes, satisfaction and knowledge of their home exercise program compared to paper based exercise programs.

There is growing evidence that Parkinson’s disease causes weakness of the respiratory muscles, and reduced strength of the inspiratory muscles has also been related to a range of respiratory dysfunctions such as dyspnoea. Substantial evidence shows that inspiratory muscle training has been shown to increase inspiratory muscle strength, reduce dyspnoea, increase exercise tolerance, and enhance quality of life in other populations. In this context, we seek to explore the effects of inspiratory muscle training in people with Parkinson’s disease. Inspiratory muscle training could be an effective intervention in rehabilitation programs for Parkinson’s disease. The potential benefits of such training could include not just increasing muscle strength but also improving daily living activities, reducing dyspnoea on exertion and improving quality of life. As respiratory abnormalities have been significantly associated with increased disability and reduced quality of life in various chronic conditions, any intervention with the potential to improve respiratory function deserves consideration.

This project aims to pilot the Promoting Resilience in Stress Management for Parents (PRISM-P) intervention in parents of young children with T1D. PRISM-P consists of four skill-based modules: stress management, goal setting, cognitive restructuring, and benefit-finding. This pilot study aims to examine the acceptability, appropriateness, feasibility, and preliminary efficacy of PRISM-P.

Procedural sedation involves the administration of sedative medications to facilitate a painful or intolerable procedure. It is commonly performed in emergency departments for reduction of a range of orthopaedic injuries, to facilitate cardioversion for tachyarrhythmias, amongst other uses. The usual practice involves one clinician performing sedation, another clinician performing a procedure, and a nurse assisting with medications, monitoring and documentation. It is generally performed in a resuscitation bay to be prepared for any complications that may arise. Procedural sedation is commonly performed in Australasian emergency departments however the evidence base for the practice of it is not as robust as many other areas. Drugs used for procedural sedation have changed over time with introduction of newer agents, however there remains a lack of evidence as to best practices. As such the administration of procedural sedation varies widely with significant variation within departments and even wider variation internationally. We are establishing a database of all procedural sedation performed at our hospital with a view to expanding this database state-wide and eventually throughout Australasia. This large dataset will allow us to analyse the sedation performed and draw associations between the patients involved, the medications used, adverse events, and procedure success rates.

The INFINiTE-CV2 Phase I trial aims to assess whether nasal delivery of an Interferon (IFN -1)/ Hyaluronic Acid formulation is safe (phase 1) in COVID-19 infection. This study is being performed to address an unmet urgent clinical need for a simple effective treatment for a pathogen of global health significance. It is hoped that this treatment is shown to be safe and effective with potential implications for both treatment and prevention of COVID-19.